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Background: Vascular drug delivery becomes a promising direction in the development of 
novel therapeutic strategies in the treatment of cardiovascular pathologies, such as hyperten-
sion. However, targeted delivery of hydrophobic substances, with poor bioavailability, 
remains a challenge. Here, we described the hypotensive effects of a low dose of curcumin 
delivered to the vascular wall using hyaluronic acid-based nanocapsules.
Methods: The group of hypertensive TGR(m-Ren2)27 rats, was administrated respectively 
with the vehicle, curcumin solution or curcumin delivered using hyaluronic acid-based 
nanocapsules (HyC12-Cur), for 7 days each, maintaining the wash-out period between 
treatments. Arterial blood pressure (systolic - SBP, diastolic – DBP) and heart rate (HR) 
were monitored continuously using a telemetry system (Data Science International), and 
Mean Arterial Pressure (MAP) was calculated from SBP and DBP.
Results: In hypertensive rats, a low dose of curcumin (4.5 mg/kg) administrated in HyC12-Cur 
for 7 days resulted in a gradual inhibition of SBP, DBP and MAP increase without an effect on HR. 
At the end of HyC12-Cur – based treatment changes in SBP, DBP and MAP amounted to −2.0±0.8 
mmHg, −3.9±0.7 mmHg and −3.3±0.7 mmHg, respectively. In contrast, the administration of 
a curcumin solution (4.5 mg/kg) did not result in a significant hypotensive effect and the animals 
constantly developed hypertension. Vascular delivery of capsules with curcumin was confirmed 
using newly developed fluorine-rich nanocapsules (HyFC10-PFOB) with a shell based on a HA 
derivative and similar size as HyC12-Cur. HyFC10-PFOB gave fluorine signals in rat aortas 
analyzed ex vivo with a 19F NMR technique after a single intragastric administration.
Conclusion: These results suggest that nanocapsules based on hyaluronic acid, the ubiqui-
tous glycosaminoglycan of the extracellular matrix and an integral part of endothelial 
glycocalyx, may represent a suitable approach to deliver hydrophobic, poorly bioavailable 
compounds, to the vascular wall.
Keywords: nanocapsules, hyaluronic acid, 19F NMR, curcumin, hypertension, targeted 
vascular delivery
Introduction
The main goal of any therapy is to achieve maximum results of the treatment while 
avoiding side effects. However, most of the drugs, used against certain pathologies, 
including cardiovascular diseases, do not have the affinity to desired targets in the 
body.1 Moreover, over 40% of approved pharmaceuticals and nearly 90% of the 
newly synthesized chemicals are sparingly soluble in an aqueous environment, and 
even they have therapeutic potential, they are rejected at the early stage of 
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research.2 Furthermore, poorly water-soluble or non- 
selective drugs often require high doses or prolonged 
infusion to reach therapeutic plasma concentrations, 
which might eventually occur toxic for organisms.3,4
Up to date, many physical, chemical and miscellaneous 
methods have been revealed to improve the properties of 
therapeutic agents.4 The most promising and developing 
concept is the use of drug delivery systems (DDSs), espe-
cially the ones of the nanometer size, ie liposomes, 
micelles, nanoparticles, etc.5 Enclosing active agents in 
DDS, enables the administration of hydrophobic or 
unstable drugs and preferential delivery of non-selective 
compounds due to the shell properties or DDS 
architecture.3,6,7 Additionally, nanoencapsulation prolongs 
drug clearance and protects pharmaceuticals from deacti-
vation or degradation, allowing for their controlled and 
sustained release.7,8
A high worldwide prevalence of cardiovascular dis-
eases has contributed to a rapid increase in interest in 
novel therapeutic strategies using DDSs, which are tar-
geted to the vascular wall. Most of those platforms are 
based on organic nanocarriers such as liposomes, which 
surface was additionally modified with specific ligands or 
coatings (eg monoclonal antibodies, peptides, growth fac-
tors, or polymers) enhancing their affinity to the 
endothelium.9–11 For example, liposomes conjugated to 
anti-ICAM-1 or anti-PECAM antibodies were capable of 
delivering antioxidant or anti-thrombotic enzymes to the 
vessel wall in models of oxidative stress,12–14 while addi-
tional covering with polyethylene glycol (PEG), prolonged 
their lifetime in the circulation.15,16 Moreover, peptide- 
coated or positively charged liposomes, as well as nano-
particles, were also shown to be effective in vasculature 
targeting of hydrophobic anti-cancer drugs and natural 
chemotherapeutics.11,17,18 Considering these facts, encap-
sulation of non-specific and lipophilic molecules like cur-
cumin, lycopene, resveratrol, or quercetin, which are 
known for their multiple health benefits including cardio- 
and vascular protection, might be useful in targeted ther-
apy and prevention of cardiovascular diseases.19–21 
Moreover, there is a growing interest in targeting hyalur-
onan-based delivery systems against eg atherosclerosis 
taking advantage of receptors for hyaluronic acid.22,23 
However, despite many different approaches, the smart 
delivery of lipophilic vasoprotective molecules to the vas-
cular wall remains a challenge including the difficulties to 
track their vascular delivery.5
DDSs may be tracked in vivo or ex vivo using fluores-
cence microscopy or ultrasonography. However, the applica-
tion of fluorinated cargo molecules as probes have recently 
attracted significant attention for medical diagnosis and 
selective imaging as they can bring an unprecedented con-
trast in 19F Magnetic Resonance Imaging (19F MRI) or 
19F Nuclear Magnetic Resonance (19F NMR) spectroscopy. 
A “second color” imaging has a wide range of advantages, ie 
19F isotope has 100% natural abundance, a spin of ½ and 
a gyromagnetic ratio comparable with a hydrogen atom 
(40.08 MHz/T for 19F and 42.58 MHz/T for 1H).24–26 
Thus, 19F MRI has great potential as a method with a high 
contrast-to-noise ratio due to the lack of background signal 
and was applied in this work to detect very low concentra-
tions of DDS ex vivo in the aorta.27
We proposed a novel application of recently developed 
and described nanocapsules, based on hyaluronic acid (HA), 
which is a ubiquitous glycosaminoglycan of the extracellular 
matrix and an integral part of the endothelial glycocalyx. 
Our previous works demonstrated that HyC12-based nano-
capsules with liquid hydrophobic cores represent 
a promising and tunable nanodelivery system for lipophilic 
active compounds via both, oral and intravenous, adminis-
tration in vivo.28,29 Interestingly, our in vitro studies 
revealed that nanocapsules were taken up by mouse liver 
sinusoidal endothelial cells and lung vascular endothelial 
cells, suggesting their possible application as 
a hydrophobic drug delivery system targeted to the vascular 
wall.28 Moreover, we showed also the potential for the 
delivery of lipophilic compounds due to their high stability 
and efficient uptake by various cells, especially the ones 
exposing CD44 receptors. The nanocapsules containing 
oleic acid cores were shown to act as an efficient anticancer 
agent while capsules with corn oil cores appeared to be non- 
toxic for various cell lines that imply their promising 
applicability.30 Therefore, the present work aimed to evalu-
ate the possible use of hyaluronan-based nanocapsules for 
drug vascular delivery. For that purpose, we tested whether 
HyC12-based nanocapsules loaded with curcumin, admini-
strated per os, would result in better hypotensive effects as 
compared with a low dose of curcumin given per os as 
a solution. Curcumin was chosen as a therapeutic agent, as 
its vasoprotective and hypotensive effects have been well 
documented in vivo, but only in relatively high doses, due to 
its poor water solubility and low bioavailability.17,31–34 
Additionally, to confirm the delivery of studied nanocarriers 
to the vessel wall, novel fluorine-rich HyFC10-based nano-
capsules were developed and administrated to rats per os, 
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and their presence in the aorta was examined ex vivo using 
19F NMR technique.
Methods
Preparation of HyC12-Based 
Nanocapsules Loaded with Curcumin 
(HyC12-Cur) and Fluorine-Rich 
HyFC10-Based Nanocapsules 
(HyFC10-PFOB)
Modifications of Hyaluronic Acid
Amphiphilic derivatives of hyaluronic acid (HA) were 
obtained by reacting HA sodium salt with either dodecy-
lamine (C12) or perfluorodecylamine (FC10). The 
obtained HA derivatives – HyC12 and HyFC10, served 
as shells of nanocapsules. The synthesis of HyC12 was 
performed following the procedure described previously,28 
while the modification of HA with perfluorinated alkyl 
chain (Figure 1) was done as described below.
500 mg of HA sodium salt (Mw≈ 150 000 g/mol, Sigma- 
Aldrich) was dissolved in 100 mL of deionized water followed 
by the addition of 30 mg of 1-ethyl-3-(3-dimethylamino- 
propyl)-carbodiimide (EDC, >99%, Sigma-Aldrich) and 
18 mg of N-hydroxysuccinimide (NHS, 98%, Sigma- 
Aldrich). The mixture was diluted with 10 mL of water and 
vigorously stirred for 30 minutes. The reaction mixture was 
heated up to 37°C and 80 mL of tetrahydrofuran (THF, p.a., 
Avantor Performance Materials Poland), 20 mL of ethanol 
(96%, p.a., Avantor Performance Materials Poland) and 
1.55 mL of 0.1 M 1H,1H,2H,2H-perfluorodecylamine 
(FC10, Santa Cruz Biotechnology) in ethanol were added. 
The reaction was carried out for 24 h under vigorous stirring 
at 37°C and followed by the dialysis of the reaction mixture 
against 1:1 v/v solution of tert-butanol (99%, Sigma-Aldrich) 
and PBS (pH=7.4, c=0.1 M, Sigma-Aldrich) for 3 days, and 
then against water for 4 days. The resulted derivative, 
HyFC10, was then freeze-dried.
To confirm modifications of HA and to calculate the 
degree of substitution (DS) by alkyl or perfluoroalkyl chains, 
the elemental analysis was applied. The DS values were 
determined based on carbon and nitrogen contents in the 
samples. A DS= 3.7% was obtained for HyFC10 and com-
parable value of DS= 3.0% was found for HyC12. 
Derivatization of HA using FC10 (HyFC10) was also con-
firmed by 19F NMR measurements (Avance III HD 400 
MHz spectrometer, Bruker), by comparing the spectra of 
the FC10 substrate and the resulting HyFC10. All character-
istic fluorine signals of FC10 were found also in the spec-
trum of HyFC10 with only slight relative shifts (Figure S1).
Formation of HyC12-Cur and HyFC10-PFOB 
Nanocapsules
The aqueous dispersion of the capsules with corn oil (Oil) 
core and HyC12 shells was obtained in a direct emulsifica-
tion process, based on the mechanical shaking and sonica-
tion (Figure 2) as described previously with some minor 
changes.28 Briefly, an aqueous solution of HyC12 (1 g/L) 
was mixed with corn oil (Sigma-Aldrich) in 1000:3 ratio 
(v/v). Then, the mixture was shaken for 15 min using 
a vortex shaker and sonicated for 30 min at room tempera-
ture in the ultrasonic bath (40 W, Sonic-6, Polsonic). The 
nanocapsules loaded with curcumin (Cur, Sabinsa Europe 
Figure 1 Scheme of hydrophobic modification of HA by perfluorinated alkyl chains.
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GmbH) were prepared in the same way using Cur solution 
in corn oil (15 g/L) instead of pure oil.
The mechanical shaking and an ultrasound-assisted 
emulsification process with a few modifications were 
also applied to obtain capsules with liquid cores containing 
fluorine, HyFC10-PFOB (Figure 2). Namely, an aqueous 
solution of HyFC10 (2 g/L) was mixed with perfluorooc-
tylbromide (PFOB, 99%, Sigma-Aldrich), in a 1000:3 ratio 
(v/v). The mechanical shaking was prolonged up to 40 min 
following 20-minute sonication. Both steps were repeated.
The obtained HyFC10-PFOB capsules dispersed in 
water were characterized with 19F NMR to confirm the 
encapsulation and to estimate the encapsulation efficiency 
(EE) of PFOB. The sodium fluoride was added as 
a standard to the sample (9 mM) and EE was calculated 
based on the integration of peaks of PFOB and 19F signal 
(Figure S2). The 19F NMR measurements revealed the 
81% encapsulation efficiency of PFOB formulation, calcu-
lated based on the known amount of added NaF reference. 
The signals from HyFC10 shells of the capsules were not 
visible in the spectrum due to much lower content as 
compared to PFOB.
Characterization of the Capsules
Sizes and zeta potentials of the capsules dispersed in water 
were determined using Dynamic Light Scattering (DLS). 
The measurements were conducted at 22°C using 
a Malvern Zetasizer Nano ZS instrument working at 
173° detection angle. The general-purpose mode was 
used as the size distribution analysis algorithm, and the 
reported data represent the averages from three series of 
measurements (10–100 runs each) and their standard 
deviations (mean ± SD, n = 3).
The stability of the capsules in the digestive system 
was examined by their incubation in the simulated gastric 
juice (0.2% (w/v) sodium chloride (Sigma-Aldrich) in 
0.7% (v/v) hydrochloric acid (35–38%, Avantor 
Performance Materials Poland), 0.32% (w/v) pepsin 
(Sigma-Aldrich), pH=1.8) for 2h. Control samples were 
incubated with PBS. DLS measurements were performed 
in the given solutions to reveal the potential degradation of 
the capsules.
The influence of low pH conditions on the encapsu-
lated Cur was studied as it might be not resistant to the 
acidity of the stomach (oral delivery).35,36 The HyC12-Cur 
capsules were incubated for 2h in the solutions with pH 
adjusted to 7.4, 3.6, 1.8 and their sizes were measured 
using DLS. The fluorescence spectra of encapsulated and 
non-encapsulated Cur (dissolved in methanol (MeOH, p.a., 
Avantor Performance Materials Poland)) were also mea-
sured at neutral (pH=7.4) and acidic (pH=1.8) conditions.
The morphology of the formed capsules was observed 
by Scanning Electron Microscopy (SEM, Hitachi S-4700). 
For that purpose, model capsules with HyC12 and 
HyFC10 shells and n-octadecane (nC18, >99%, GC, 
Sigma-Aldrich) cores were prepared. The capsules were 
obtained analogously to the previously described proce-
dures, but the emulsification (10-minute mechanical shak-
ing and 30-minute sonication) was performed at 32°C, 
above the melting point of nC18. After completing the 
procedure, the dispersions of the capsules were cooled to 
room temperature, which resulted in the solidification of 
nC18 cores of the capsules. Capsules with already solid 
cores were deposited on silicon substrates. The silicon 
wafer was prepared by cleaning with “piranha” solution 
(a mixture of H2SO4 (96%, Avantor Performance 
Materials Poland) and H2O2 (30%, Avantor Performance 
Materials Poland), 1:1 (v/v)) followed by coating with 
cationic polyelectrolyte (immersion in polyethylenimine, 
PEI, branched, Mw≈25,000 g/mol, Sigma-Aldrich, solution 
(1 g/L) and sonication for 5 min) to enhance the adhesion 
of negatively charged capsules. Then, the surface was 
carefully rinsed with water and dried in a stream of 
argon. Finally, the capsules with solid cores were depos-
ited on the silicon wafer coated by PEI. The surface was 
again gently rinsed with water and dried in a stream of 
argon before SEM measurements.
Animals
The experiment involved male, hypertensive, heterozy-
gous TGR(m-Ren2)27 rats (n=6), obtained from Institute 
of Clinical and Experimental Medicine (Prague, Czech 
Republic), representing a unique transgenic model of the 
severe renin-angiotensin system (RAS)-dependent hyper-
tension, in which the introduction of the murine renin 
transgene to the rat genome leads to the spontaneous 
Figure 2 Scheme of the formation of the capsule.
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increase in blood pressure.37 Normotensive Wistar rats 
(n=12) from Jagiellonian University Medical College, 
Faculty of Pharmacy (Krakow, Poland) were also used. 
After the delivery, animals undergo a few days of accli-
matization followed by the handling procedure to tame rats 
with a touch. During the experiment, the hypertensive rats 
were kept in individual cages, according to the manufac-
turers’ recommendations, to avoid the interference of tele-
metry signals and mutual damaging of the suture and 
transmitters after the implantation, leading to faster recov-
ery. During the convalescence period, topical analgesic 
was applied to the wound to reduce animals’ pain and 
distress after the surgery. Wistar rats were housed in col-
ony cages, as they were used in a separate experiment. All 
animals were kept in individually-ventilated cages in con-
trolled environmental conditions (20–24°C; 55% ± 10% of 
humidity; 12h light/dark cycle) according to the European 
Union animal welfare regulations. Before and during 
entire experiments, rats had free access to food and 
water. Cages were additionally equipped with elements 
that enriched the environment: blocks for grinding teeth 
and rest houses. All procedures involving animals, includ-
ing telemetry transmitters’ implantation, compounds 
administration and sacrificing, were approved by the II 
Local Animal Ethics Commission at the Polish Academy 
of Sciences following the Ministry of Agriculture and 
Rural Development and European Union guidelines (per-
mits no. 82/2018, 164/2018, 23/2019).
Experimental Protocols
Assessment of Hypotensive Effects of Curcumin-Rich 
HyC12-Based Nanocapsules as Compared with 
Curcumin Solution on the Progression of 
Hypertension in TGR(m-Ren2)27 Rats
The experiment was conducted in TGR(m-Ren2)27 rats 
(n=6). At the age of 6 weeks, animals were separated into 
individual cages and implanted with telemetry blood pres-
sure transmitters HD-S10 (Data Science International) to 
the abdominal aorta, according to the manufacturer’s out-
lines with minor changes. Briefly, after an incision of 
abdominal skin and musculature, the abdominal aorta 
was exposed, and the catheter of the transmitter was intro-
duced upstream into the vessel. The body of the transmit-
ter was placed in the abdominal cavity and sutured. During 
the whole procedure, rats remainded under inhalation 
anesthesia with isoflurane (1–2%). After the recovery per-
iod and baseline measurements, at the age of 8 weeks, 
when the hypertension was fully developed, the 
experiment was started and data (systolic blood pressure 
- SBP, diastolic blood pressure – DBP and heart rate - HR)
was collected daily in 10 min intervals. Mean Arterial
Pressure (MAP) was calculated based on SBP and DBP
according to the formula: MAP = 2/3 DBP + 1/3 SBP.
Blood pressure and heart rate data were normalized to the
first day values and expressed as an average change.
Rats were assigned into one group and received tested 
agents according to the following plan: 1st week - Control 
(no treatment), 2nd week – curcumin solution (Cur), 3rd 
week – washout (no treatment) and 4th week – HyC12- 
Cur. Curcumin alone was prepared as a solution of curcu-
min in corn oil (2 g/L) and administrated per gavage, while 
HyC12-Cur was given as a solution of encapsulated cur-
cumin in drinking water (45 mg/L), which consumption 
was daily monitored. Different routes of administration 
were necessary to obtain an equal dose of curcumin – 
4.5 mg/kg, in both experimental groups. The concentration 
of HyC12-Cur solution was adjusted to the daily water 
intake of TGR(m-Ren2)27 rats, which was precisely mon-
itored for a couple of days before the experiment. TGR 
(m-Ren2)27 rats were characterized by the increased water 
intake (15 mL/100g b.w.), which is most likely 
a consequence of their hypertensive phenotype. The upre-
gulated RAS system results in increased urination and 
water consumption, as Angiotensin II is physiologically 
involved in the regulation of body water homeostasis.38 
Thus, to achieve the daily dose of 4.5 mg/kg b.w. of the 
curcumin the administration volume was adjusted to 
10 mL/100 g b.w., which guaranteed the full dose intake. 
In case the HyC12-Cur solution was consumed within 24h 
the bottles were refilled with pure water to maintain free 
access to fluids.
Detection of Fluorine-Rich HyFC10-Based 
Nanocapsules in Aorta After Single Oral 
Administration
Wistar rats (approx. 400 g b.w.) were assigned into 2 
groups: control (n=8), receiving a vehicle (water) and 
HyFC10-PFOB group (n=4), treated with fluorine-rich 
HyFC10-based nanocapsules dispersed in water to verify 
if nanocapsules based on HA derivative might be detected 
in a vascular wall. The aqueous dispersion of the capsules 
was administrated by gavage in a single dose, in a volume 
of 10 mL/kg b.w., and 8 h later animals were anesthetized 
by i.p. ketamine (100 mg/kg) - xylazine (10 mg/kg) injec-
tion and sacrificed. Afterward, the circulatory system was 
washed out with DPBS (Dulbecco, Gibco) and organs 
International Journal of Nanomedicine 2021:16 submit your manuscript | www.dovepress.com                          
DovePress
1381
Dovepress Czyzynska-Cichon et al
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
were fixed in situ using 4% buffered formalin perfusion to 
avoid vessels collapsing. Aorta was dissected and stored in 
formalin until further ex vivo detection of HyFC10-PFOB 
with 19F NMR spectroscopy analysis.
Ex vivo NMR measurements were performed using 
a horizontal 9.4T Bruker BioSpec 94/20 scanner. To provide 
a high SNR, a custom-built transmit-receive, double-resonant 
1H-19F, four-turn, 12 mm internal diameter strip-solenoid 
radio-frequency coil was used. For 19F NMR spectroscopy, 
excised intact aortas immersed in formalin were placed in 2 mL 
Eppendorf tubes together with a glass vial filled with 5 µL 
0.1% solution of 2,2,2-trifluoroethanol (TFE, Sigma Aldrich), 
containing approximately 200 nM of fluorine atoms, as 
a fluorine concentration reference. The same reference vial 
was used for NMR measurements of all aorta samples. 
Additionally, to obtain the reference spectrum of HyFC10- 
PFOB, the aqueous solution of the nanocapsules was analyzed. 
The following parameters of the Singlepulse sequence were 
used for measurements: the repetition time 3s, the number of 
averages 4800 and a total measurement time 4h.
Statistical Analysis
All results are presented as mean values ± SD unless 
otherwise stated. The normality of data distribution and 
variances homogeneity were evaluated using Shapiro– 
Wilk and Levene’s tests, respectively. Depending on the 
properties of variables parametric, Student’s t-test or the 
non-parametric Mann–Whitney U-test was used to assess 
the statistical significance between the experimental and 
control groups at the level of *P < 0.05, **P < 0.01, and 
***P < 0.001. Significant differences between studied 
groups are marked with †. Calculations were performed 
using Statistica 12.0.
Results
Physicochemical Characterization of 
Nanocapsules Based on HA Derivatives
Size and Zeta Potential
The nanocapsules with liquid lipophilic cores, corn oil, 
and shells based on amphiphilic HA derivatives were 
fabricated (HyC12-Oil) and used as carriers of curcumin 
(HyC12-Cur). In addition, novel capsules with fluorine- 
rich liquid cores made of PFOB and similar HA-based 
shells (HyFC10-PFOB) were formed for the first time 
and applied to confirm the vascular location of admini-
strated capsules using 19F NMR. The physicochemical 
properties of formulations including size (hydrodynamic 
diameter) and zeta potentials were investigated using the 
DLS method.
All types of used oil-in-water formulations were char-
acterized by the comparable hydrodynamic diameters of 
ca. 400 nm (Table 1). Similar distributions of the intensity- 
weighted hydrodynamic diameters were found, but the 
narrowest one was observed for HyC12-Oil (Figure S3). 
Some differences were observed for zeta potential values 
that were found less negative for the capsules loaded with 
Cur and PFOB as compared to HyC12-Oil. Different cores 
used in the studied capsules (Oil, Cur and PFOB) influence 
the organization of the shell-forming macromolecules that 
affect the exposition of ionic groups at the capsules’ sur-
face. Moreover, the shell of HyFC10-PFOB capsules con-
tained perfluorinated side chains that additionally influence 
the conformation of the shell macromolecules. However, 
in spite of different zeta potential values, all the capsules 
were found stable in an aqueous environment likely due to 
the contribution of other than electrostatic stabilizing fac-
tors (eg steric stabilization).
Stability in Simulated Gastric Juice
Low pH conditions present in the simulated gastric juice 
did not affect the stability of nanocapsules. Despite sig-
nificantly different environments, samples did not exhibit 
macroscopic changes and had a very similar average size 
as well as low size distribution (PdI) (Figure S4). The 
slight broadening of the size distribution in the simulated 
gastric juice could be related to a different ionic strength 
and pH value of the environment. The lowest value of pH 
for these studies was selected based on the typical acidity 
of human stomach juice (pH=1-2) as compared with pH of 
the rat stomach (pH=3-5).39
Stability of Curcumin in Low pH Conditions
Freshly prepared HyC12-Cur capsules in the environments 
with different pH values (pH=7.4, 3.6, and 1.8, respec-
tively for different pH values in human and rat stomach) 
exhibited practically the same average sizes and their dis-
tributions (Figure S5).39 After 2h incubation, the average 
sizes slightly increased (the most in the lowest pH) but no 
Table 1 Average Hydrodynamic Diameters and Zeta Potentials 
Values of the Fabricated Oil-in-Water Formulations
HyC12-Oil HyC12-Cur HyFC10-PFOB
Diameter [nm] 389 ± 5 403 ± 20 407 ± 11
Zeta potential [mV] −29.1 ± 0.3 −17 ± 1 −17 ± 1
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additional fractions that could be assigned to the disinte-
gration of the capsules were observed.
The fluorescence of encapsulated Cur stayed unaf-
fected after changing the pH from 7.4 to 1.8 while free 
Cur dissolved in MeOH after adjusting pH to 1.8 by 
addition of HCl decreased significantly that may be related 
to its partial degradation (Figure S6).
Morphology
The nanocapsules were deposited on a silicon surface and 
visualized by SEM (Figure S7). The images of both sys-
tems, based on HyC12 and HyFC10, revealed smooth 
spherical objects with diameters somewhat smaller than 
the ones determined via DLS. It can be rationalized as 
DLS measurements provide hydrodynamic diameters that 
are typically larger than the diameters of dry objects 
determined by SEM. Importantly, differences in viscosity, 
density, composition, phase of the cores that also imply 
variations of oil/water interfacial tension may result in 
different assembling of the polysaccharide forming the 
shells of the nanocapsules and also different sizes of 
those spherical objects. Nevertheless, the studied nanocap-
sules had comparable sizes regardless of the small differ-
ences between the applied HA derivatives.
Hypotensive Effects of Low Dose 
Curcumin Administrated in HyC12-Based 
Capsules in TGR(m-Ren2)27 
Hypertensive Rats
Untreated, control animals were characterized by progres-
sively increasing blood pressure for 7 days (Figure 3). 
Mean systolic (SBP) and diastolic blood pressure (DBP) 
rose gradually (~ 7±4 mmHg/day) and reached 192±14 
mmHg and 136±15 mmHg, respectively. The application 
of curcumin solution in a low dose of 4.5 mg/kg did not 
affect the progression of hypertension, as SBP, DBP and 
MAP were not reduced significantly in comparison with 
the control after 7 days of the treatment (Figure 3). In 
contrast, the administration of HyC12-Cur, in the same 
low dose of 4.5 mg/kg, limited the increase in SBP, DBP 
and MAP. The earliest changes occurred on the 2nd day of 
the treatment in DBP, while the reduction of SBP, and 
MAP was observed starting from the 4th day of the treat-
ment. After 7 days of the treatment, the changes in mean 
SBP, DBP, and MAP were −2.0±0.8 mmHg, −3.9±0.7 
mmHg and −3.3±0.7 mmHg, respectively, as compared 
with the control (Figure 4). HyC12-Cur had no effects on 
heart rate.
19F NMR-Based Characteristics and 
Detection of HyFC10-PFOB in the 
Vascular Wall of the Rat Aorta After 
Single Oral Administration
HyFC10-PFOB capsules measured using 19F NMR dis-
played characteristic peaks of PFOB: -CF2Br located at 
−66 ppm, -CF3 located at −84 ppm, while multiplet around 
124 ppm was assigned to -CF2- groups (see Figure 5 and 
Figure S2 for detailed assignments). The peak at −78.8 
ppm was assigned to -CF3 group of TFE (δ= 77.86 ppm), 
which was chosen as a convenient reference as its signal is 
well-separated from all PFOB peaks.
To confirm the delivery of HyFC10-PFOB to the vas-
cular wall, 19F NMR spectra of the aortas taken from the 
rats subjected to a single injection of HyFC10-PFOB 
nanocapsules (see methods for details) were measured 
and compared with 19F NMR signal from the aorta taken 
from the control rats. Two measurements were rejected in 
the control group due to artifacts, leaving n=6. In the case 
of HyFC10-PFOB treated animals, one measurement was 
rejected (no fluorine was detected), leaving n=3. In aortas 
from the control group, no fluorine was detected, while in 
the spectra of HyFC10-PFOB treated rats, two main peaks 
located at −81.6 ppm and −87.6 ppm, symmetrically 
around the position of CF3 peak in the spectra of HyFC10- 
PFOB capsules were found (Figure 5). The small residual 
peaks were also observed at ~-65 ppm and around −124 
ppm, close to the positions of CF2Br and multiplet of CF2 
in the original spectrum HyFC10-PFOB, respectively. 
However, as these peaks were close to the limit of detec-
tion, we considered them negligible.
Discussion
In the present work, we demonstrated that in hypertensive 
TGR(m-Ren2)27 rats, a representative model of RAS- 
dependent hypertension,40–42 a low dose of curcumin 
(4.5 mg/kg) administrated in HyC12-based nanocapsules, 
resulted in mild hypotensive effects, visible as a gradual 
fall in SBP, DBP and MAP. In contrast, a low dose of 
curcumin given as the oil solution at the same dose of 
4.5 mg/kg was ineffective. Although we do not have direct 
evidence of the curcumin delivery to the vascular wall, in 
a proof-of-concept study, taking advantage of MRI-based 
detection of purposely synthesized HyFC10-PFOB, we 
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demonstrated that the components of nanocapsules were 
detected in aorta after a single administration of HyFC10- 
PFOB by oral gavage. Altogether, this study provides pre-
liminary evidence that the nanocapsules composed 
of hyaluronan, a ubiquitous glycosaminoglycan of the extra-
cellular matrix, and an integral part of endothelial glycoca-
lyx, may represent a suitable approach to deliver 
hydrophobic, poorly bioavailable compounds, to the vascular 
wall. This conclusion stays in line with our previous studies 
showing the uptake of nanocapsules based on HA derivatives 
by endothelial cells in vitro,28 supporting their possible appli-
cation for targeted vascular delivery.
Curcumin is a naturally occurring polyphenolic com-
pound, widely consumed with a diet that exerts beneficial 
vasoprotective effects. Several studies demonstrated that pro-
longed administration of curcumin attenuated hypertension 
development, improved arterial elasticity, reduced oxidative 
stress, and preserved endothelial function in both, animals and 
humans.31–33,43–46 In various models of hypertension, curcu-
min elicited hypotensive actions attributed to numerous mole-
cular targets, including restoring eNOS function, increasing 
glutathione plasma levels or down-regulation of angiotensin- 
converting enzyme (ACE) and angiotensin II (Ang II) type-1 
receptor.31,33,46 Unfortunately, due to the poor water solubility 
and low bioavailability of curcumin, as a consequence of its 
low intestine absorption and rapid metabolism,47 vasoprotec-
tive effects of curcumin could only be achieved with very high 
doses (50–1000 mg/kg) and special formulations.
Figure 3 Progressive changes in SBP, DBP, MAP and HR in hypertensive TGR(m-Ren2)27 rats after administration of HyC12-Cur, curcumin in solution or in controls. 
Notes: Statistical significance between the experimental and control groups is marked with asterisks: *P < 0.05, **P < 0.01, and ***P < 0.001. Significant differences between 
studied groups are marked with † (†P < 0.05, ††P < 0.01). 
Abbreviations: ΔSBP, change in systolic blood pressure; ΔDBP, change in diastolic blood pressure; ΔMAP, change in mean arterial pressure; ΔHR, change in heart rate.
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Our experiment was performed in TGR(m-Ren2)27 
rats, representing a unique model of RAS-dependent 
hypertension, relevant to the human pathology.40–42 
Furthermore, therapy of TGR(m-Ren2)27 rats with drugs 
commonly used to treat hypertension in humans, such as 
calcium channel blockers or ACE inhibitors, suppressed 
blood pressure elevation in this model,37,48,49 supporting 
its relevance to the pathophysiology of human hyperten-
sion. Accordingly, the mild hypotensive effect of curcumin 
enclosed in HyC12-based nanocapsules shown in this 
work in TGR(m-Ren2)27 rats suggests that HyC12-Cur 
may also have a therapeutic significance for humans.
The most important finding of this study was the hypo-
tensive effect of encapsulated curcumin, given in a low dose 
of 4.5 mg/kg that was at least partially ascribed to its direct 
delivery to the vessel wall. Although we did not provide 
definitive evidence for the targeted vascular delivery of 
curcumin in HyC12-Cur, the 19F NMR – based detection 
of capsules’ components in rat aortas seems to confirm that 
nanocarriers based on HA derivatives were targeted to the 
vascular wall. Indeed, in the current study, taking advantage 
of the specially designed fluorine-rich HyFC10-PFOB 
nanocapsules we established a novel methodology for the 
ex vivo detection of HA-based nanocapsules using 
19F NMR. For that purpose, HA was modified by attaching 
perfluorinated alkyl chain leading to the formation of HA- 
derivative with similar content of hydrophobic chains as in 
the case of HyC12. Liquid cores of HyFC10-based nano-
capsules were made of PFOB (the perfluorinated oil), which 
is intensively studied in ultrasound or 19F MRI imaging, as 
well as an artificial oxygen carrier, due to its biocompat-
ibility and good tolerance in both animals and humans.50 
Figure 4 Changes in SBP, DBP, MAP and HR in hypertensive TGR(m-Ren2)27 rats after 7 days of HyC12-Cur administration as compared to curcumin administered in 
solution and to controls. 
Notes: Statistical significance between the experimental and control groups is marked with asterisks: **P < 0.01 and ***P < 0.001. Significant differences between studied 
groups are marked with † (†††P < 0.001). 
Abbreviations: ΔSBP, change in systolic blood pressure; ΔDBP, change in diastolic blood pressure; ΔMAP, change in mean arterial pressure; ΔHR, change in heart rate.
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According to 19F NMR analysis, the encapsulation efficacy 
of PFOB in HyFC10-based capsules was as high as 81%. 
Given the physicochemical properties of PFOB, ie its parti-
tion coefficient, logP=6.9 and extremely low water solubi-
lity (10−9 M), resulting in very poor bioavailability, it is 
clear that administration of PFOB requires encapsulation or 
preparation of an aqueous emulsion. Thus, all the observed 
fluorine content in a given tissue upon administration of 
HyFC10-PFOB capsules should come from the encapsu-
lated PFOB. Components of HyFC10-PFOB capsules were 
detected in the vascular wall of aortas using 19F NMR 
spectroscopy. The exact origin of the two main 19F peaks 
(−81.1 and −87.1 ppm) observed in the aorta samples 
(Figure 5) is not clear, due to the significant alteration of 
the fluorine spectra, but their positions suggest the terminal 
CF3 groups in PFOB as an origin (−83.8 ppm). The split of 
this peak into two, as well as significant broadening of the 
spectra lines, may result from different local environments 
in the vicinity of the terminal CF3 groups, or local magnetic 
field inhomogeneity due to aorta microstructure. The shift 
of the spectrum peaks in model biological microenviron-
ments was reported previously as a result of the interaction 
of PFOB with POPC bilayer, as well as hexane molecules.51 
Strong reduction of the signals originating from CF2Br and 
CF2 groups may be attributed to the immobilization of the 
PFOB backbone, which results in broadening of the spec-
trum and limited detection at the experimental conditions. 
Thus, the observed spectral features may be related to the 
disintegration of nanocapsules after their delivery and 
incorporation of PFOB into the aorta tissue, combined 
with immobilization of their molecular backbone. The 
terminal CF3 groups may remain relatively more mobile 
distributed in two chemically/physically different surround-
ings that resulted also in two chemical shifts of the signal. 
Based on that assumption, integration of the peaks’ areas as 
compared to the integrated signal from the reference peak, 
allowed the calculation of the average PFOB concentration 
in the tissue reaching 0.36 ± 0.06 µM PFOB per 1g of the 
aorta (based on wet mass calculation).
Herein, we demonstrated that hyaluronic acid-based 
capsules, depending on the applied liquid core and with 
minor shell modifications, could serve either for the deliv-
ery of active compounds or as a carrier of the perfluorinated 
contrast agent. The outer shell chemistry and fundamental 
physicochemical characteristics were comparable between 
the obtained capsules (HyC12-Oil, HyC12-Cur and 
HyC12-PFOB) that imply similar interactions with the 
biological environment, despite differences in the core 
composition. Our previous in vitro studies demonstrated 
efficient cellular uptake of HyC12-based nanocapsules 
Figure 5 Representative 19F NMR spectrum of an excised rat aorta (black) overlaid on a HyFC10-PFOB solution spectrum (red). 
Note: Both spectra were measured with TFE as a reference (δ=−77.3 ppm relative to CFCl3) using the Bruker BioSpec 94/20 scanner.
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and intracellular release of the cargo thanks to the presence 
of hyaluronidase, an enzyme cutting HA-based chains.30 
Thus, together with the current results confirming their 
stability in simulated gastric juice, it indicates that nano-
capsules are stable in extracellular fluid and the inner 
environment of the capsules can affect the cells only after 
enzymatic degradation of the HA-based shells inside the 
cells. In fact, the capsules seem to protect curcumin dis-
solved in their cores against the acidic environment present 
in the stomach. Interestingly, the previous pharmacokinetic 
study in vivo using fluorescent probes revealed that 
HyC12-based nanocapsules, administrated to mice in 
a single dose, were accumulated preferentially in livers 
and lungs, with even greater intensity in the 
endotoxemia.28 Given the fact that endotoxemia is asso-
ciated with the glycocalyx shedding and the overexpression 
of endothelial hyaluronic receptors, these results may sug-
gest the interaction between HyC12-based nanocapsules 
and the endothelium. However, possible mechanisms have 
not been investigated yet. The shell of HyC12 nanocapsules 
is based on HA, the natural polysaccharide and the glyco-
calyx constituent, recognized by hyaluronan receptors 
including CD44 and Hyaluronic Acid Receptor for 
Endocytosis (HARE) and uptaken from the 
bloodstream.52 CD44 and HARE are mainly located on 
the surface of endothelial cells and macrophages in the 
vascular wall and their overexpression is observed during 
inflammatory processes associated with many diseases 
including sepsis, ischemia-reperfusion, and atherosclerosis, 
becoming a promising target for vascular drug delivery.22,53 
Recent studies in animal models of atherosclerosis have 
shown that HA-based nanoparticles were selectively upta-
ken through the CD44 and HARE receptors overexpressed 
in atherosclerotic plaque in the vascular wall, resulting in 
therapeutic effects.22,23,54 Furthermore, Hou et al demon-
strated that the treatment of high fat diet-fed rats with 
curcumin enclosed in CD44-specific HA-based micelles 
for 2 weeks reduced the area of atherosclerotic lesions in 
rats’ aortas supporting a possibility of the vascular delivery 
of HA-based nanocarriers.55 Accordingly, hypotensive 
effects of HyC12-Cur observed in this study, as well as 
the detection of HyFC10-PFOB components in rat aortas, 
might indeed be due to the HA–based uptake of HyC12- 
based nanocapsules to the vascular wall.
Moreover, HyC12-Cur did not affect the heart function, 
while administration of curcumin solution resulted in 
a decrease of HR without influencing the blood pressure. 
These different effects might be explained by the distinct 
biodistribution of Cur solution as compared with HyC12- 
Cur, which additionally supports the targeted delivery of 
nanocapsules to the vessel wall. In fact, curcumin was 
cardioprotective by improving heart function, without 
affecting the blood pressure, in rats with myocardial 
infarction.56 Moreover, the administration of the curcumin 
directly to the isolated perfused rat hearts evoked negative 
chronotropic and inotropic effects.57 Although the exact 
mechanism behind these actions has not yet been eluci-
dated, it was proven by the pharmacokinetic study that 
curcumin accumulates in rat hearts, even after single-dose 
administration.58 These results stay in line with our obser-
vations and suggest that curcumin given in solution might 
be uptaken by the cardiomyocytes and thus directly affect 
the heart rate. In turn, the shell composition of HyC12-Cur 
might enhance nanocapsules affinity to the endothelial 
cells, resulting in HyC12-Cur accumulation in the vascular 
wall. Thus, it might well be that HyC12-Cur as compared 
with Cur solution had distinct effects on vascular and heart 
function.
On the other hand, the efficacy of encapsulated curcu-
min might be also related to improved bioavailability and 
increased absorption from the gastrointestinal tract. 
Indeed, our recent in vivo study brought the evidence 
that HyC12-based nanocapsules were well absorbed from 
the gastrointestinal tract and distributed through the circu-
lation after oral administration.28 Thus, enclosing curcu-
min in HyC12-Cur may improve its bioavailability and 
prolong the clearance time, enhancing its therapeutic 
potential even at low doses.
Conclusions
To sum up, the nanocapsules composed of hyaluronate- 
based shell and liquid oleic core represent a suitable 
approach to deliver hydrophobic, poorly bioavailable 
compounds to the vascular wall as exemplified here by 
the demonstration of the hypotensive effect in TGR 
(m-Ren2)27 rats of low dose curcumin encapsulated in 
such nanocapsules (HyC12-Cur). Nanocapsules with per-
fluorinated cores (HyFC10-PFOB) having comparable 
sizes and the shell composition to original HyC12-based 
capsules were specially designed to confirm by 19F NMR 
spectroscopy the presence of the cores of the HyFC10- 
PFOB capsules in the vascular walls, after a single admin-
istration. Altogether, this work demonstrated vascular 
delivery of HyC12-based capsules, though the increased 
pharmacological efficacy of encapsulated curcumin might 
be also related to the improved bioavailability of curcumin 
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administrated in HyC12-Cur. Obviously, further optimiza-
tion and mechanistically oriented studies are needed to 
better understand the mechanisms of the uptake and reten-
tion of nanocarriers based on HA derivatives in the vas-
cular wall.
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